Dean Capital Investments Management LLC purchased a new position in shares of Amgen, Inc. (NASDAQ:AMGN) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 1,664 shares of the medical research company’s stock, valued at approximately $324,000.
A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. Ruggie Capital Group grew its stake in shares of Amgen by 297.1% during the 4th quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock worth $26,000 after purchasing an additional 101 shares during the period. Arlington Partners LLC grew its stake in shares of Amgen by 86.7% during the 4th quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock worth $27,000 after purchasing an additional 65 shares during the period. Massey Quick Simon & CO. LLC grew its stake in shares of Amgen by 710.5% during the 4th quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock worth $30,000 after purchasing an additional 135 shares during the period. Essex Investment Management Co. LLC acquired a new stake in shares of Amgen during the 4th quarter worth approximately $39,000. Finally, Contravisory Investment Management Inc. acquired a new stake in shares of Amgen during the 4th quarter worth approximately $50,000. 77.96% of the stock is owned by institutional investors.
In related news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $188.88, for a total value of $377,760.00. Following the sale, the director now owns 14,988 shares of the company’s stock, valued at approximately $2,830,933.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.27% of the stock is currently owned by company insiders.
A number of equities research analysts have recently commented on the stock. Goldman Sachs Group reaffirmed a “buy” rating and set a $232.00 price objective on shares of Amgen in a research note on Tuesday, December 4th. Barclays reaffirmed a “neutral” rating and set a $195.00 price objective on shares of Amgen in a research note on Tuesday, December 4th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $223.00 price objective on shares of Amgen in a research note on Tuesday, December 4th. JPMorgan Chase & Co. set a $192.00 price objective on shares of Amgen and gave the stock a “neutral” rating in a research note on Tuesday, December 4th. Finally, Royal Bank of Canada reaffirmed a “neutral” rating and set a $182.00 price objective on shares of Amgen in a research note on Tuesday, December 4th. Twelve research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $209.63.
Amgen stock opened at $186.70 on Friday. Amgen, Inc. has a 1 year low of $163.31 and a 1 year high of $210.19. The firm has a market capitalization of $116.18 billion, a P/E ratio of 12.97, a P/E/G ratio of 2.28 and a beta of 1.21. The company has a debt-to-equity ratio of 2.36, a quick ratio of 2.57 and a current ratio of 2.79.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, January 29th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.26 by $0.16. Amgen had a net margin of 35.35% and a return on equity of 66.74%. The firm had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $5.88 billion. During the same quarter last year, the company earned $2.89 EPS. As a group, analysts forecast that Amgen, Inc. will post 13.97 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $1.45 dividend. The ex-dividend date is Thursday, May 16th. This represents a $5.80 dividend on an annualized basis and a yield of 3.11%. Amgen’s dividend payout ratio is currently 40.28%.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Highlight Press and is the property of of Highlight Press. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://highlightpress.com/2019/03/24/dean-capital-investments-management-llc-purchases-new-stake-in-amgen-inc-amgn.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.